Exscientia plc (EXAI)

USD 4.84

(0.0%)

Market Cap (In USD)

633.17 Million

Revenue (In USD)

20.07 Million

Net Income (In USD)

-145.96 Million

Avg. Volume

668.39 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
3.8-7.91
PE
-
EPS
-
Beta Value
0.835
ISIN
US30223G1022
CUSIP
30223G102
CIK
1865408
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. David Hallett Ph.D.
Employee Count
-
Website
https://www.exscientia.ai
Ipo Date
2021-10-01
Details
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.